Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
DarĂŠ Bioscience is a clinical-stage biopharmaceutical company committed to the ad...
DarĂŠ Bioscience is a clinical-stage biopharmac...
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...
Headquartered in Mountain View, California, IGM...
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing thera...
At Catabasis Pharmaceuticals, our mission is to...
Ionis is a sustainably profitable, multi-product company with a pipeline of more t...
Ionis is a sustainably profitable, multi-produc...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
Sienna Biopharmaceuticals, Inc. is a clinicalâstage biopharmaceutical company fo...
Sienna Biopharmaceuticals, Inc. is a clinicalâ...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.